(Q53521179)

English

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Emmanouil Saloustros

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

D Mavroudis

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

N Malamos

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

S Kakolyris

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

I Boukovinas

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

P Papakotoulas

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

N Kentepozidis

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

N Ziras

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

V Georgoulias

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

0 references

publication date

1 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1333-1340

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25935793%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV213

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53521179&oldid=1963947694"